Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway
Oncogenic activation of the KRAS gene via point mutations occurs in 20–30% of patients with non-small cell lung cancer (NSCLC). The RAS-RAF-ERK and RAS-PI3K-AKT pathways are the major hyper-activated downstream pathways in RAS mutation, which promotes the unlimited lifecycle of cancer cells and thei...
Main Authors: | Huanling Lai, Yuwei Wang, Fugang Duan, Ying Li, Zebo Jiang, Lianxiang Luo, Liang Liu, Elaine L. H. Leung, Xiaojun Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.00958/full |
Similar Items
-
Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
by: Yuwei Wang, et al.
Published: (2018-07-01) -
The Role of Raf-mediated Signalling Pathways for Motoneuron
by: Pei, Geng
Published: (2000) -
The quaternary assembly of KRas4B with Raf-1 at the membrane
by: Hyunbum Jang, et al.
Published: (2020-01-01) -
A YWHAZ Variant Associated With Cardiofaciocutaneous Syndrome Activates the RAF-ERK Pathway
by: Ivan K. Popov, et al.
Published: (2019-04-01) -
Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
by: Aoife A. Nolan, et al.
Published: (2021-04-01)